Neutrophil extracellular traps released by neutrophils impair revascularization and vascular remodeling after stroke

Tags

  • Category: Articles

Neutrophil-extracellular-traps-released-by-neutrophils-impair-revascularization-and-vascular-remodeling-after-stroke

Neutrophil extracellular traps released by neutrophils impair revascularization and vascular remodeling after stroke

Authors: Lijing Kang, Huilin Yu, Xing Yang, Yuanbo Zhu, Xiaofei Bai, Ranran Wang, Yongliang Cao, Haochen Xu, Haiyu Luo, Lu Lu, Mei-Juan Shi, Yujing Tian, Wenying Fan & Bing-Qiao Zhao

Abstract Neovascularization and vascular remodeling are functionally important for brain repair after stroke. We show that neutrophils accumulate in the peri-infarct cortex during all stages of ischemic stroke. Neutrophils producing intravascular and intraparenchymal neutrophil extracellular traps (NETs) peak at 3-5 days. Neutrophil depletion reduces blood-brain barrier (BBB) breakdown and enhances neovascularization at 14 days. Peptidylarginine deiminase 4 (PAD4), an enzyme essential for NET formation, is upregulated in peri-ischemic brains. Overexpression of PAD4 induces an increase in NET formation that is accompanied by reduced neovascularization and increased BBB damage. Disruption of NETs by DNase 1 and inhibition of NET formation by genetic ablation or pharmacologic inhibition of PAD increases neovascularization and vascular repair and improves functional recovery. Furthermore, PAD inhibition reduces stroke-induced STING-mediated production of IFN-β, and STING knockdown and IFN receptor-neutralizing antibody treatment reduces BBB breakdown and increases vascular plasticity. Collectively, our results indicate that NET release impairs vascular remodeling during stroke recovery.

Reference:  Kang, L., Yu, H., Yang, X. et al. Neutrophil extracellular traps released by neutrophils impair revascularization and vascular remodeling after stroke. Nat Commun 11, 2488 (2020). Retrieved from https://www.nature.com/ncomms/

Product Highlights:

The authors used Bio X Cell's anti-mouse Ly6G (Clone: 1A8), anti-mouse IFNAR-1 (Clone: MAR1-5A3), and mouse IgG isotype control (Clone: MOPC-21) in this research study.


Back to News

Meet Our Leaders

Learn more about the team behind the gold standard in vivo antibodies.

Discover Bio X Cell

Learn more about our proven expertise and comprehensive antibody solutions.

See Our Impact

Discover the Bio X Cell Fund’s mission to improve the health of our community

Explore Our Latest

See our latest articles and whitepapers for scientific insights and ideas

Don’t see what you need?

Consult With Bio X Cell to Enable Your Next Breakthrough Discovery

Whether you need antibody customization or high-volume production, Bio X Cell is committed to advancing your therapeutic innovations.

Contact Us